Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: business – Page 20

Mike Kelly is President & Chief Executive Officer of NervGen Pharma Corp. (https://nervgen.com/), a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease.

NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in an initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.

Mr. Kelly brings three decades of pharmaceutical experience playing instrumental roles in the creation, development and strengthening of several companies.

Most recently, Mr. Kelly served as President of US Operations for Adapt Pharma, Inc. from March 2016 to June 2019, and played a key leadership role in the development and commercialization of NARCAN (naloxone HCl) Nasal Spray in the US and Canada and in the eventual sale to Emergent BioSolutions for US$735 million.

Prior to his tenure at Adapt Pharma, Inc., Mr. Kelly served as the Chief Executive Officer and a Director of Covis Pharmaceuticals, Inc., where, along with its European affiliate, grew and sold the company assets for US$1.2 billion. Mr. Kelly was also a member of the founding management team of Azur Pharma Limited, a specialty pharmaceutical company, and later, following a strategic merger, served as the Senior Vice President of Sales and Marketing for Jazz Pharmaceuticals Inc. Mr. Kelly has also held various commercial and medical roles at Guilford Pharmaceuticals Inc., ViroPharma Incorporated and TAP Pharmaceuticals Inc. and has been a Director of ARS Pharmaceuticals Inc. since May 2019.

Mr. Kelly holds a Bachelor of Science in business administration from The College of New Jersey and a Master of Business Administration from Rider University.

Continue reading “Mike Kelly — President & CEO, NervGen Pharma — Innovative Treatments To Enable Nervous System Repair” | >

The name of the conference will be lifeboat foundation conference for polymaths futuristics and visionaries.

The place will be this hotel.

https://maps.app.goo.gl/sdG14SRcrJEJGYGH6

With nice accommodation equipped with fitness swimming pool sauna Jacuzzi and restaurant.

Please help me organise it…

Dear All Polymaths I will arrange the conference for polymaths like all of you.

Continue reading “Charoen Thani Hotel, Khon Kaen. · 260 Sri Chant Rd, Nai Mueang, Mueang Khon Kaen District, Khon Kaen 40000, Thailand” | >

People with AI are going to replace people without AI.

SAN FRANCISCO (AP) — Artificial intelligence’s recent rise to the forefront of business has left most office workers wondering how often they should use the technology and whether a computer will eventually replace them.

Those were among the highlights of a recent study conducted by the workplace communications platform Slack. After conducting in-depth interviews with 5,000 desktop workers, Slack concluded there are five types of AI personalities in the workplace: “The Maximalist” who regularly uses AI on their jobs; “The Underground” who covertly uses AI; “The Rebel,” who abhors AI; “The Superfan” who is excited about AI but still hasn’t used it; and “The Observer” who is taking a wait-and-see approach.

Read more | >

Microsoft on Monday said it was enhancing its AI offerings with new autonomous agent capabilities as the tech titan aims to accelerate business adoption of artificial intelligence.

AI agents are specialized programs designed to perform autonomously, such as sifting through sales leads or handling customer service inquiries.

The AI agent has become the newest buzzword for major software companies that are investing billions in powerful AI models, which they believe will shape the future of computing.

Read more | >

Although UBTech is leaving 10% of work for humans in management, other AI tech is being specifically developed for that niche: OpenAI’s new framework, Swarm, allows AI agents to collaborate and independently execute complex tasks, potentially boosting business efficiency.

Artificial intelligence agents are everywhere, quietly reshaping industries and automating tasks we didn’t think possible a few years ago. Unlike basic automation, these AI agents can handle complex jobs, think independently and learn from their environment. The result? Healthcare, finance and logistics businesses are seeing rapid gains in efficiency — and, in some cases, doing away with manual work altogether.

What are AI agents exactly? They’re software programs that carry out specific tasks without constant supervision. Whether handling customer requests, diagnosing medical conditions or predicting market trends, AI agents are versatile workhorses. Instead of waiting for humans to input every command, these agents operate autonomously, reacting to real-time data and adjusting their actions accordingly.

Microsoft recently unveiled new AI tools allowing healthcare organizations to build customized AI agents for appointment scheduling, clinical trial matching, and patient triage. These agents are designed to streamline workflows and improve efficiency, helping healthcare providers manage workloads and enhance patient care.

Read more | >

Fortunately, the past decade has experienced a boom, with over 200 startups bringing novel cancer therapies—primarily antibodies, viruses, or cells—into clinical trials aiming to find alternatives to toxic chemotherapy. Despite these innovations, chemotherapy remains an essential yet toxic part of cancer care. In Pittsburgh, a small team of scientist-entrepreneurs and oncologists started meeting every Friday morning before work, collaborating to search for a new chemistry, one that could replace toxic chemotherapies. Their search soon focused on compelling research about novel ultra-small nanomedicine chemistry that carried potent drugs deep into solid tumors while sparing healthy organs.

This new nanomedicine chemistry fascinated Dr. Sam Rothstein, a scientist-entrepreneur with 20+ years of nanomedicine research experience spanning academia and industry. “We could make a real positive impact on patients,” says Rothstein. “We know that nanomedicines, which keep potent therapies out of healthy organs, improve quality of life. But this novel ultrasmall chemistry could go even further, saving lives by reaching remote cancer cells that current therapies can’t touch.”

Dr. Rothstein set to work building a new company, calling on connections made over a 10+-year career as a life science startup CEO and CSO, where he founded and grew two nanomedicine startups from academic discoveries. After months of market, regulatory, and business research, Duo Oncology was born.

Read more | >

Expanding Healthy Human Lifespan for All — Dr. Mehmood Khan, MD — CEO, Hevolution Foundation.

Dr. Mehmood Khan, MD is the Chief Executive Officer of Hevolution Foundation (https://www.hevolution.com/), a first of its kind non-profit organization that funds research through grants and provides investments in biotech to incentivize healthspan science across disciplines and borders for the benefit of all. Established by a Saudi Royal Decree, with its headquarters in Riyadh, with additional international hubs to support the expansion and execute the global mission, it’s vision is to expand healthy human lifespan for the benefit of all humanity.

Hevolution Foundation aims to be positioned as a global leader, catalyst, partner, and convener, to increase the number of scientists entering the field, to increase the investable opportunities in the field of aging, and to help shape the regulatory and government environment.

Dr. Khan also currently serves as the Executive Chairman of Life Biosciences Inc. where he joined the company in April 2019 as the Chief Executive Officer and Board Member. Life Biosciences was founded to advance scientific research and develop innovative new therapies to improve and extend healthy lives for everyone.

Dr. Khan previously served as Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, a Fortune 50 company employing upwards of 250,000 employees across 22 brands. At PepsiCo, Dr. Khan played a pivotal role in the company’s global R\&D efforts to create breakthrough innovations in food, beverages, and nutrition, including the incorporation of healthier and more nutritious offerings across its portfolio. Dr. Khan also oversaw PepsiCo’s global sustainability initiatives based on the belief that success in business is inextricably linked to the sustainability of the world we share.

Continue reading “Dr. Mehmood Khan, MD — CEO, Hevolution Foundation — Expanding Healthy Human Lifespan for All” | >

At Impactsure Technologies, we’ve helped clients of banks generate guarantees and contracts through preapproved clauses in a matter of a few seconds without the need to go through a complex process of vetting that would have otherwise taken many days. It not only enhances the customer experience but also makes it easier to manage the processes efficiently. The clients are able to manage their contracts well, manage the content, ensure appropriate vetting and scrutiny are done effectively, manage the timelines, and incorporate the electronic signing options in a seamless way.

As contract management complexities continue to increase in the banking and enterprise sectors, the adoption of GenAI emerges as strategically crucial for organizations seeking to enhance operational efficiency, mitigate risks and maintain regulatory compliance. By harnessing the power of AI-driven automation, banks and enterprises can streamline contract processes, optimize resource utilization and confidently navigate the complicated legal landscape.

A combination of GenAI, NLP and ML represents a paradigm shift in contract management, empowering banks and enterprises to easily manage the complexities of the modern business environment with agility and resilience. By embracing AI-driven solutions, organizations can unlock new opportunities for growth, innovation and sustainable success in an increasingly competitive and rapidly evolving environment.

Read more | >

“The grid needs new electricity sources to support AI technologies that are powering major scientific advances, improving services for businesses and customers, and driving national competitiveness and economic growth,” Google Senior Director for Energy and Climate Michael Terrell, said in a statement.

“This agreement helps accelerate a new technology to meet energy needs cleanly and reliably, and unlock the full potential of AI for everyone,” Terrell added.

Read more | >